{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:04:58Z","timestamp":1791461098482,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"DOI":"10.7759\/cureus.41424","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:29:30Z","timestamp":1688603370000},"source":"Crossref","is-referenced-by-count":3,"title":["A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment"],"prefix":"10.7759","author":[{"given":"Shaunak","family":"Mangeshkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Nazarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Varrias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Spanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Borkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd Al Deen","family":"Alhuarrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Kishore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T","family":"Faillace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.886266","article-title":"The evolving story of multifactorial chylomicronemia syndrome","volume":"9","author":"Paquette M","year":"2022","unstructured":"Paquette M, Bernard S. The evolving story of multifactorial chylomicronemia syndrome. Front Cardiovasc Med. 2022, 9:886266. 10.3389\/fcvm.2022.886266","journal-title":"Front Cardiovasc Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5551\/jat.10702","article-title":"Diagnosis and management of type I and type V hyperlipoproteinemia","volume":"19","author":"Gotoda T","year":"2012","unstructured":"Gotoda T, Shirai K, Ohta T, et al.. Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb. 2012, 19:1-12. 10.5551\/jat.10702","journal-title":"J Atheroscler Thromb"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia--current diagnosis and future therapies","volume":"11","author":"Brahm AJ","year":"2015","unstructured":"Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol. 2015, 11:352-362. 10.1038\/nrendo.2015.26","journal-title":"Nat Rev Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/BF01477060","article-title":"Diagnosis and management of type I and type V hyperlipoproteinemia","volume":"56","author":"Middelhoff G","year":"1978","unstructured":"Middelhoff G, Mordasini R, Zebe H, Greten H. Diagnosis and management of type I and type V hyperlipoproteinemia. Klin Wochenschr. 1978, 56:457-460. 10.1007\/BF01477060","journal-title":"Klin Wochenschr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000624","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019, 139:1046-1081. 10.1161\/CIR.0000000000000624","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait A","year":"2019","unstructured":"Chait A, Eckel RH. The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment. Ann Intern Med. 2019, 170:626-634. 10.7326\/M19-0203","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.593931","article-title":"A comprehensive update on the chylomicronemia syndrome","volume":"11","author":"Goldberg RB","year":"2020","unstructured":"Goldberg RB, Chait A. A comprehensive update on the chylomicronemia syndrome. Front Endocrinol (Lausanne). 2020, 11:593931. 10.3389\/fendo.2020.593931","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron JS","year":"2019","unstructured":"Dron JS, Wang J, Cao H, et al.. Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol. 2019, 13:80-88. 10.1016\/j.jacl.2018.10.006","journal-title":"J Clin Lipidol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New insights into the pathophysiology of dyslipidemia in type 2 diabetes","volume":"239","author":"Taskinen MR","year":"2015","unstructured":"Taskinen MR, Bor\u00e9n J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015, 239:483-495. 10.1016\/j.atherosclerosis.2015.01.039","journal-title":"Atherosclerosis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2010.11.004","article-title":"Etiology and risk of lactescent plasma and severe hypertriglyceridemia","volume":"5","author":"Tremblay K","year":"2011","unstructured":"Tremblay K, M\u00e9thot J, Brisson D, Gaudet D. Etiology and risk of lactescent plasma and severe hypertriglyceridemia. J Clin Lipidol. 2011, 5:37-44. 10.1016\/j.jacl.2010.11.004","journal-title":"J Clin Lipidol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.01.014","article-title":"Chylomicronemia syndrome: familial or not?","volume":"14","author":"Warden BA","year":"2020","unstructured":"Warden BA, Minnier J, Duell PB, Fazio S, Shapiro MD. Chylomicronemia syndrome: familial or not?. J Clin Lipidol. 2020, 14:201-206. 10.1016\/j.jacl.2020.01.014","journal-title":"J Clin Lipidol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa838","article-title":"10-year comparative follow-up of familial versus multifactorial chylomicronemia syndromes","volume":"106","author":"Belhassen M","year":"2021","unstructured":"Belhassen M, Van Ganse E, Nolin M, et al.. 10-year comparative follow-up of familial versus multifactorial chylomicronemia syndromes. J Clin Endocrinol Metab. 2021, 106:1332-1342. 10.1210\/clinem\/dgaa838","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000846","article-title":"Elevated serum triglycerides in the prognostic assessment of acute pancreatitis: a systematic review and meta-analysis of observational studies","volume":"51","author":"Wang Q","year":"2017","unstructured":"Wang Q, Wang G, Qiu Z, He X, Liu C. Elevated serum triglycerides in the prognostic assessment of acute pancreatitis: a systematic review and meta-analysis of observational studies. J Clin Gastroenterol. 2017, 51:586-593. 10.1097\/MCG.0000000000000846","journal-title":"J Clin Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab360","article-title":"Rare variants in triglycerides-related genes increase pancreatitis risk in multifactorial chylomicronemia syndrome","volume":"106","author":"Paquette M","year":"2021","unstructured":"Paquette M, Amyot J, Fantino M, Baass A, Bernard S. Rare variants in triglycerides-related genes increase pancreatitis risk in multifactorial chylomicronemia syndrome. J Clin Endocrinol Metab. 2021, 106:3473-3482. 10.1210\/clinem\/dgab360","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2018.03.086","article-title":"Clinical features and outcomes of severe, very severe, and extreme hypertriglyceridemia in a regional health service","volume":"12","author":"Zafrir B","year":"2018","unstructured":"Zafrir B, Jubran A, Hijazi R, Shapira C. Clinical features and outcomes of severe, very severe, and extreme hypertriglyceridemia in a regional health service. J Clin Lipidol. 2018, 12:928-936. 10.1016\/j.jacl.2018.03.086","journal-title":"J Clin Lipidol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000436438.60145.5a","article-title":"Issues in hypertriglyceridemic pancreatitis: an update","volume":"48","author":"Scherer J","year":"2014","unstructured":"Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014, 48:195-203. 10.1097\/01.mcg.0000436438.60145.5a","journal-title":"J Clin Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2012.08.007","article-title":"Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg\/dL in patients with severe hypertriglyceridemia","volume":"6","author":"Christian JB","year":"2012","unstructured":"Christian JB, Arondekar B, Buysman EK, Johnson SL, Seeger JD, Jacobson TA. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg\/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012, 6:450-460. 10.1016\/j.jacl.2012.08.007","journal-title":"J Clin Lipidol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutres.2022.02.001","article-title":"Both low-fat and low-carbohydrate diets reduce triglyceride concentration in subjects with multifactorial chylomicronemia syndrome: a randomized crossover study","volume":"101","author":"Fantino M","year":"2022","unstructured":"Fantino M, Paquette M, Blais C, Saint-Pierre N, Bourque L, Baass A, Bernard S. Both low-fat and low-carbohydrate diets reduce triglyceride concentration in subjects with multifactorial chylomicronemia syndrome: a randomized crossover study. Nutr Res. 2022, 101:43-52. 10.1016\/j.nutres.2022.02.001","journal-title":"Nutr Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1185\/030079905x43677","article-title":"Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel","volume":"21","author":"Shepherd J","year":"2005","unstructured":"Shepherd J, Betteridge J, Van Gaal L. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin. 2005, 21:665-682. 10.1185\/030079905x43677","journal-title":"Curr Med Res Opin"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton JR","year":"2007","unstructured":"Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007, 99:22-31. 10.1016\/j.amjcard.2006.11.018","journal-title":"Am J Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet D","year":"2020","unstructured":"Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, et al.. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020, 41:3936-3945. 10.1093\/eurheartj\/ehaa689","journal-title":"Eur Heart J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2020.1768848","article-title":"Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia","volume":"18","author":"Nurmohamed NS","year":"2020","unstructured":"Nurmohamed NS, Dallinga-Thie GM, Stroes ES. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. Expert Rev Cardiovasc Ther. 2020, 18:355-361. 10.1080\/14779072.2020.1768848","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S345072","article-title":"Angiopoietin-like protein 3 (ANGPTL3) inhibitors in the management of refractory hypercholesterolemia","volume":"14","author":"Kosmas CE","year":"2022","unstructured":"Kosmas CE, Bousvarou MD, Sourlas A, Papakonstantinou EJ, Pe\u00f1a Genao E, Echavarria Uceta R, Guzman E. Angiopoietin-like protein 3 (ANGPTL3) inhibitors in the management of refractory hypercholesterolemia. Clin Pharmacol. 2022, 14:49-59. 10.2147\/CPAA.S345072","journal-title":"Clin Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01516-y","article-title":"Evinacumab: first approval","volume":"81","author":"Markham A","year":"2021","unstructured":"Markham A. Evinacumab: first approval. Drugs. 2021, 81:1101-1105. 10.1007\/s40265-021-01516-y","journal-title":"Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/157947-a-case-of-type-v-hyperlipoproteinemia-resistant-to-insulin-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:22Z","timestamp":1707508942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/157947-a-case-of-type-v-hyperlipoproteinemia-resistant-to-insulin-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.41424","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,5]]}}}